Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer

NCT03912818 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

7

Enrollment

OTHER

Sponsor class

Stopped Difficulty with enrollment

Conditions

Bladder Adenocarcinoma
Bladder Mixed Adenocarcinoma
Bladder Squamous Cell Carcinoma
Bladder Urothelial Carcinoma
Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant
Infiltrating Bladder Urothelial Carcinoma With Giant Cells
Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation
Infiltrating Bladder Urothelial Carcinoma With Trophoblastic Differentiation
Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant
Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant
Infiltrating Bladder Urothelial Carcinoma, Nested Variant
Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant

Interventions

DRUG: Carboplatin
DRUG: Cisplatin
PROCEDURE: Cystectomy
DRUG: Doxorubicin
BIOLOGICAL: Durvalumab
DRUG: Gemcitabine
DRUG: Methotrexate
DRUG: Vinblastine

Sponsor

Stanford University

Collaborators

[object Object]